Xencor swings to Q3 net profit of $39.44 million; Q3 revenue rises to $116.52 million
XNCR•Xencor reported third-quarter net income attributable to shareholders of $39.44 million, versus a year-earlier loss, as revenue rose to $116.52 million. The company projected year-end cash, cash equivalents and marketable debt securities of $480 million–$500 million, with resources expected to fund operations into 2029.
1. Quarterly results and outlook
Xencor swung to third-quarter 2026 net income attributable to shareholders of $39.44 million, while revenue rose to $116.52 million, primarily from Alexion and Incyte royalties and Astellas milestone revenue. Research and development expenses climbed 55% year over year to $84.3 million, primarily due to higher development-program costs; Xencor projected year-end cash, cash equivalents and marketable debt securities of $480 million–$500 million, with resources funding operations into 2029.
2. Kidney cancer study
Xencor plans a global Phase 3 study of XmAb819 in advanced kidney cancer by the end of 2027, subject to regulatory feedback.
